The results from double immunohistofluorescence analyses have revealed that the expression levels of all of these biomarkers were significantly enhanced in a small subset of CD133+ PC cells dispersed through the intermediate compartment in malignant prostate tissues as well as the bulk tumor mass of CD133− PC cells in prostatic adenocarcinomas relative to non-malignant prostate tissue specimens from patients (Figure 4 and Figure S1). This evidence concerns the gene PROM1 and pachyonychia congenita.